激酶S6K1研究现状及展望  

Research on Progress and Prospect of Kinase S6K1

作　　者：张会[1,2] 梁俊玉[1] 张继[1] 

机构地区：[1]西北师范大学生命科学学院,兰州730070 [2]四川大学华西医院生物治疗国家重点实验室,成都610041

出　　处：《生物医学工程学杂志》2014年第4期935-938,949,共5页Journal of Biomedical Engineering

基　　金：国家自然科学基金资助项目(2012ZX09102-101-002);西北师范大学青年教师科研能力提升计划项目资助(NWNU-LKQN-12-7);西北师范大学博士引进项目资助

摘　　要：肥胖症是一种严重威胁人类健康的代谢疾病,已成为全球关注的公共健康问题。激酶S6K1是哺乳动物雷帕霉素靶蛋白(mTOR)下游一个重要的效应子,调控并介导着包括肥胖症、Ⅱ型糖尿病、癌症等在内的多种代谢疾病。作为这些疾病的重要治疗靶点,激酶S6K1已成为当前研究热点。本文主要对激酶S6K1的功能、分子调控机理、所参与调控的疾病及其小分子抑制剂的研究现状进行综述,并对其发展前景进行展望。Obesity is a prevalent metabolic disorder,which seriously affects human health and has become the world＇s public health problem. Kinase S6K1, an important downstream effector of mammalian target of rapamycin （mTOR）, influences specific pathological responses, including obesity, type 2 diabetes and cancer. Presently, S6K1 has become an attractive therapeutic target in the treatment of these disorders. Here, the functions of kinase S6K1, its molecular regulation mechanisms, related pathogenesis of disease and relevant small molecular inhibitors are reviewed. Finally, the prospect of research toward S6K1 is expected as well.

关 键 词：激酶S6K1 肥胖病 分子机理 抑制剂 

分 类 号：R589.2[医药卫生—内分泌]